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Abstract
Background: One of the pathological hallmarks of Alzheimer’s disease (AD) is the deposition of the ~4 kDa
amyloid b protein (Ab) within lesions known as senile plaques. Ab is also deposited in the walls of cerebral blood
vessels in many cases of AD. A substantial proportion of the Ab that accumulates in the AD brain is deposited as
Amyloid, which is highly insoluble, proteinaceous material with a b-pleated-sheet conformation and deposited
extracellularly in the form of 5-10 nm wide straight fibrils. As g-secretase catalyzes the final cleavage that releases
the Ab42 or 40 from amyloid b -protein precursor (APP), therefore, it is a potential therapeutic target for the
treatment of AD. g-Secretase cleavage is performed by a high molecular weight protein complex containing
presenilins (PSs), nicastrin, Aph-1 and Pen-2. Previous studies have demonstrated that the presenilins (PS1 and PS2)
are critical components of a large enzyme complex that performs g-secretase cleavage.
Methods: In this study we used RNA interference (RNAi) technology to examine the effects of small-interfering
RNA (siRNA) against PS1 on expression levels of PS1 and Ab42 in IMR-32 Cells using RTPCR, western blotting and
immunofluorescence techniques.
Results: The results of the present study showed down regulation of PS1 and Ab42 in IMR32 cells transfected with
siRNA against PS1.
Conclusion: Our results substantiate the concept that PS1 is involved in g-secretase activity and provides the
rationale for therapeutic strategies aimed at influencing Ab42 production.
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Background
A key step in the pathogenesis of AD is proteolysis of
APP that results in the formation of the amyloid-b pro-
tein (Ab), the principle protein component of the char-
acteristic cerebral plaques of the disease [1]. Ab is
produced from APP ﬁrst by the action of b-s e c r e t a s e ,a
membrane-tethered enzyme that resembles pepsin and
other water-soluble aspartyl proteases [2]. This proteoly-
sis leads to membrane shedding of the large luminal/
extracellular APP domain. The 99-residue membrane-
bound remnant is then cleaved in the middle of its
transmembrane region by g -secretase, releasing Ab and
again near the inner leaﬂet at the b site to release the
APP intracellular domain (AICD) [3]. Rare mutations in
the APP gene, found in and around the Ab region cause
familial early-onset Alzheimer’s disease (EOAD) and
these mutations alter the production of Ab or its aggre-
gation properties [4]. Several contemporaneous observa-
tions provided critical clues for the identiﬁcation of the
elusive g-secretase. First, genes encoding the multi-pass
membrane proteins presenilin-1 and presenilin-2
(PS1&PS2) were discovered in a search to identify other
genes associated with familial EOAD. The disease-caus-
ing missense mutations were soon found to alter how g
-secretase cuts APP leading to increased proportions of
longer, more aggregation-prone forms of Ab [5]. Sec-
ond, knock out of PS-1 dramatically reduced g -secretase
cleavage of APP [6]. Third, the types of compounds that
could inhibit g -secretase contained moieties typically
found in aspartyl protease inhibitors [7]. These ﬁndings
led to the identiﬁcation of two conserved transmem-
brane aspartates in the multi-pass presenilin that are cri-
tical for g -secretase cleavage of APP, suggesting that
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[8]. Presenilin is cut into two pieces, an N-terminal frag-
ment (NTF) and a C-terminal fragment (CTF), the for-
mation of which is gated by limiting cellular factor(s)
[9]. NTF and CTF remain physically associated in a high
molecular weight complex and are metabolically stable
[10]. These and other results suggested that the NTF-
CTF heterodimer is the biologically active form [11,12].
The NTF and CTF each contributes one of the essential
and conserved aspartates, suggesting that the g -secre-
tase active site might be at the interface between these
two presenilin fragments. In strong support of this
hypothesis, transition-state analogue inhibitors of g
-secretase, designed to interact with the active site of
the protease, bind directly to presenilin NTF and CTF
[13,14]. However, presenilin alone is not proteolytically
active. This fact, along with the requirement for other
factors for presenilin NTF/CTF formation and the
assembly of presenilin into large complexes, suggested
that g- secretase is composed of other subunits besides
presenilins. Further, Presenilin 1 (PS1) knockout mice
and inhibitor cross-linking studies have provided con-
vincing evidence that PS1 is an essential subunit for g-
secretase processing [15]. Recently, small interfering
RNA (siRNA) has been found to be important in regu-
lating protein expression in organisms varying from
plants to mammals [16]. By activating a sequence-speci-
fic RNA degradation process, siRNA post transcription-
ally inhibits protein expression of the specific gene
[17,18]. We exploited siRNA technology to understand
the regulation of g-secretase by presenilin-1 and its
impact on Ab42 production in IMR-32 neuronal cell
line. The results showed that there was PS1 down regu-
lation and lesser Ab42 production, suggesting PS1 is
involved in g-secretase activity and provides the ratio-
nale for therapeutic strategies aimed at influencing Ab
production.
Methods
2.1 IMR-32 cell culture
Human neuroblastoma IMR-32 cells were obtained from
NCCS, Pune, India and maintained at 37°C in an atmo-
s p h e r eo f9 5 %a i ra n d5 %C O 2 in Eagle’s minimum
essential medium supplemented with 2 mM L-glutamine
and Earle’s BSS, 1.5 g/L bicarbonate, 0.1 mM nonessen-
tial amino acids, 1.0 mM Sodium pyruvate and 10%
heat-inactivated fetal bovine serum. Media was changed
every two days. Passage was done in 1:3 ratios and dou-
bling time was 24 Hours.
2.2 siRNA transfection against PS1
In a six well tissue culture plate, 2 × 10
5 cells were
seeded per well in 2 ml antibiotic-free normal growth
medium supplemented with FBS. The cells were
incubated at 37°C in a CO2 incubator until the cells
were 60-80% confluent for 18-24 hours. Transfection of
PS1 siRNA (50 pmoles, 75 pmoles and 100 pmoles
siRNA) and control siRNA duplex was done with the
transfection reagent after checking the cell viability with
the trypan blue and the cells were incubated for 5-7
hours at 37°C in a CO2 incubator. Then 1 ml of normal
growth medium was added, containing 2 times the nor-
mal serum and antibiotics concentration (2× normal
growth medium) without removing the transfection
mixture and the cells were incubated for an additional
18-24 hours. After incubation, media was aspirated and
replaced with 1X normal growth medium and incubated
for 48 hours. After 48 hours cells were used for RNA
(Taurus Scientific) and protein isolation, used for RT-
PCR and western blotting analysis respectively.
2.3 Semi-Quantitative PCR amplification
Expression of PS1 after transfecting IMR-32 cells with
siRNA against PS1 was evaluated by PCR analysis using
sequence specific primers corresponding to the
sequence in the open reading frame. 10 μl PCR mixture
was prepared in 1× PCR buffer consisting of 1 unit of
Taq polymerase, 2 μMo fe a c hp r i m e rf o rG A P D Ha n d
PS1 along with 200 μM of each dNTP. For amplification
of PS 1 and GAPDH, cDNA products (1 μl) were sub-
jected to reverse transcriptase PCR analysis on a gradi-
ent thermal cycler instrument (Eppendorff, Germany).
PCR cycle for PS1 and control siRNA comprised of
initial denaturation at 94°C for 2 min. The amplification
was then carried out for 35 cycles consisting 45 sec
each for 94°C (denaturation), 62°C (annealing) and 72°C,
1 min (elongation). Final extension was done at 72°C for
10 min. PCR cycle of GAPDH, which was used as inter-
nal control, comprised of initial denaturation at 94°C for
2 min. The amplification was then carried out for 35
cycles consisting 45 sec each for 94°C (denaturation),
56.8°C (annealing) and 72°C, 1 min (elongation). Final
extension was done at 72°C for 10 min. Densitometric
analysis of the products was done using SCION IMAGE
software (Scion Image Corporation, Fredrick, MD, USA)
to compare the relative mRNA expression of PS1 gene
at various concentrations of PS1 siRNA duplex.
2.4 Immunoblotting
Immuno detection of PS 1
Following SDS-PAGE (12%), proteins were transferred
to NC membrane with semi dry apparatus (Bio Rad)
using transfer buffer [25 mM Tris, 192 mM glycine, 20%
(vol/vol) methanol, pH 8.3]. The blots were incubated
with 5% non fat dried milk for at least 2 h and then
washed three times for 10 min each with PBS plus 0.1%
Tween-20. Blots were incubated for 2.5 h at room tem-
perature with anti PS1antibody (diluted 1:250 in PBS)
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body was removed, and the blots were washed three
times for 10 min each with PBS plus 0.1% Tween-20.
The blots were then incubated in horseradish peroxi-
dase-labeled goat anti-rabbit IgG (diluted 1:5,000 in
PBS) for 45 min at room temperature. After washing
the membrane for at least 1 hour, the proteins were
visualized by diaminobenzidine (DAB) from Bangalore
Genei, India The densitometric analysis of the protein
bands was carried out using SCION IMAGE software
(Scion Image Corporation, Fredrick, MD, USA) to com-
pare the relative expression of proteins.
Immuno detection of Ab42
Following SDS-PAGE (16%), proteins were transferred
to NC membrane with semi dry apparatus (Bio Rad)
using transfer buffer [25 mM Tris, 192 mM glycine, 20%
(vol/vol) methanol, pH 8.3]. The blots were incubated
with 5% non fat dried milk for at least 2 h and then
washed three times for 10 min each with PBS plus 0.1%
Tween-20. Blots were incubated for 2.5 h at room tem-
perature with anti Ab42 antibody (diluted 1:250 in PBS)
(Santa cruz Biotechnology, Inc, USA). The primary anti-
body was removed, and the blots were washed three
times for 10 min each with PBS plus 0.1% Tween-20.
The blots were then incubated in horseradish peroxi-
dase-labeled goat anti-rabbit IgG (diluted 1:5,000 in
PBS) for 45 min at room temperature. After washing
the membrane for at least 1 hour, the proteins were
visualized by diaminobenzidine (DAB), from Bangalore
Genei, India. The densitometric analysis of the protein
bands was carried out using SCION IMAGE software
(Scion Image Corporation, Fredrick, MD, USA) to com-
pare the relative expression of proteins.
Immunofluorescence staining of PS1 and Ab42
IMR-32 cells were transfected with PS1 siRNA as
described earlier and cells were fixed with the 1:1 Acet-
one/Methanol fixative for 20 minutes at 20°C. After 20
minutes fixative was aspirated and washed three times
with the 1X PBS and proceeded for immunostaining. For
immunostaining, fixed cells were blocked in the blocking
buffer for 60 minutes at 37°C. After 60 minutes blocking
buffer was aspirated and incubated with the anti PS1, anti
Ab42 (1:50 dilutions) (Santa cruz Biotechnology, Inc,
USA) for 24 hours at 4°C. After 24 hours incubation, cells
were rinsed three times with 1X PBS and incubated with
FITC labelled secondary antibody (1:50 dilutions) for 2
hours in dark at 37°C. The cells were visualized under the
fluorescence microscope and the images were recorded.
Results
3.1 Effect of siRNA on the expression of presenilin 1 (PS1)
gene in IMR-32 cells determined by RT-PCR
After attaining 60-80% confluency, IMR-32 cells were
transfected with varying concentrations (50 pmoles,7 5
pmoles, and 100 pmoles) of PS1 siRNA and 100 pmoles
of control or scrambled siRNA. Semiquantitative PCR
analysis of PS1 showed reduction in PS1mRNA in IMR-
32 cells with increasing concentration of PS1 siRNA with
maximum reduction at 100 pmoles (Figure 1).
3.2 Effect of siRNA on the content of PS1 peptide in IMR-
32 cells
Western blotting analysis of PS1 showed a decreased
protein expression with increase in concentration of PS1
siRNA. In other words there was a dose dependent
decrease in PS1 protein levels with increased concentra-
tion of PS1 siRNA(Figure 2).
3.4 Effect of PS1 siRNA on Ab42 production in IMR-32
cells
Ab42 expression was studies were carried out using
western blotting, after IMR32 cells were transfected with
the PS1 siRNA, 50 pmoles PS1 siRNA was able to
reduce the Ab42 expression, but at 75 pmoles and 100
pmoles of PS1 siRNA the expression was completely
reduced (Figure 3).
3.5 Immunofuorescence analysis of PS1 and Ab42
In order to confirm the results obtained from western
blotting further immunoflourescence was carried out
after transfecting IMR-32 cells with the control siRNA
and PS1 siRNA in the same concentrations (50 pmoles,
75 pmoles and 100 pmoles) using antibodies against
PS1 and Ab42. As is evident from Figure 4 and 5, the
expression levels of PS1and Ab42 after transfection
almost ceased at 75 and 100 pmole concentration.
Therefore, down regulation of PS1 using PS1 siRNA
results in down regulation of Ab42 as well.
Discussion
g-Secretase activity is responsible for the cleavage of
the transmembrane domain of the amyloid precursor
protein (APP), releasing the amyloid peptide Ab and
the APP intracellular domain. Ab is a major compo-
nent of the amyloid plaques characteristic of Alzhei-
mer’sd i s e a s e .P r e s e n i l i n s( P S 1a n dP S 2 )a p p e a rt ob e
essential for g-secretase cleavage and form an essential
part of the g-secretase complex. PS1 knockout mark-
edly inhibits g-secretase cleavage [19], whereas a PS2
knockout has no apparent effect on g-secretase activity
[20], probably owing to compensation by the more
widely expressed PS1. Recent studies have identified PS1
as a part of g- secretase complex. To test the role of
PS1 in Ab4 2p r o d u c t i o na n df i n do u tn e wd r u ga n d
gene therapy for AD, in the present study IMR-32 cells
were transfected with siRNA against PS1gene, and in
order to interfere with transcription of PS1 gene, and
then determined the levels of PS1 mRNA, PS1 and
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pression of PS1 gene in IMR-32 cells decreased the pro-
duction of Ab42, suggesting that PS1 contributes to g-
secretase activity. The final step of Ab biogenesis is the
processing of CTFg by g-secretase within the bAPP trans-
membrane domain. With the single exception of the
Swedish bAPP mutation (K670 to N and M671 to L) all
the identified changes linked to early onset familial Alz-
heimer disease (FAD) affect g-secretase processing to
specifically increase the levels of Ab42 [21]. To date over
50 FAD linked mutations in the chromosome 14 encoded
presenilin 1 (PS1) have been identified, and several more
in presenilin 2 (PS2). Previous studies have identified sev-
eral proteins that bind PS1 but their roles at least partly
appear to be related to the function of PS1, other than g-
secretase activity such as regulation of apoptosis and cal-
cium signaling [22]. On the other hand studies on mutant
presenilins in transgenic animals have shown increase in
the relative level of Ab42 production [23,24]. The block-
ing expression of PS1 protein using siRNA results in a
loss of g-secretase activity. In this study, we wanted to
know whether suppression of PS1 could regulate g-secre-
tase activity in IMR-32 cells and regulate Ab42
production. The cell line was characterized by the
increased g-secretase activity and Ab42 production in AD
[25]. The fact that PS1 is at least partially limiting the
Ab42 production suggests that g-secretase is indeed a
complex including PS1 and the complex activity which
can be increased by the expression or reinforcement of
any one of its components. AbPP is cleaved by b-secre-
tase to CTFb, which is subsequently processed by g-
secretase to Ab40/42 and CTFg50. A 79-residue fragment
between the two cleavage sites has not yet been detected.
Multiple studies indicate that g-secretase is a large multi-
subunit enzyme [26].
Based on mutagenesis and inhibitor cross-linking stu-
dies, it has been suggested that PS1 constitute the cata-
lytically active subunit of g-secretase. However, PS1 is
n o ts u f f i c i e n tf o rg-secretase activity in vitro and multi-
ple subunits have been identified that are essential for
generation of the active enzyme. Several of these subu-
nits are apparently limiting for g-secretase activity in the
cell. Since increase in Ab42 is consistently linked to AD
pathogenesis [26], the finding that levels of PS1 can reg-
ulate the production of this fragment makes it impor-
tant candidate for evaluation in AD. The reduction in
Figure 1 RT-PCR analysis of PS1 (a) agarose gel electrophoresis and (b) densitometric analysis. Values are mean ± SD (N = 5) Lane 1:
Non siRNA transfected IMR-32 cells; Lane 2: Control siRNA transfected IMR-32 cells; Lane 3: Transfection Reagent transfected IMR-32 cells; Lane 4:
50 pmoles PS1 siRNA transfected IMR-32 cells; Lane 4: 75 pmoles PS1 siRNA transfected IMR-32 cells; Lane 5: 100 pmoles PS1 siRNA transfected
IMR-32 cells. Values are mean ± SD (N = 5). *** p < 0.001 significantly different from csiRNA.
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Page 4 of 9Figure 2 Effect of PS1 siRNA on the protein levels of PS1 (a) Immunoblot analysis of PS1 (b) densitometric analysis.6 0μgp r o t e i n s
from IMR 32 cells after PS1 transfection at different concentrations were subjected to westren blot analysis using an anti PS1 antibody (1:250
dilutions). Lane 1: Non siRNA Transfected IMR-32 Cells; Lane 2: Control siRNA; Lane 3: 50 pmoles PS1siRNA; Lane 4: 75 pmoles PS1 siRNA; Lane 5:
100 pmoles PS1 siRNA. Values are mean ± SD (N = 5). *** p < 0.001 significantly different from csiRNA.
Figure 3 Effect of PS1 siRNA on the protein levels Ab42 (a) Immunoblot analysis of Ab42 (b) densitometric analysis.6 0μg proteins of
IMR 32 cells after PS1 transfection at different concentrations were subjected to western blot analysis using anti Ab42 antibody (1:250 dilutions).
Lane 1: Non siRNA Transfected IMR-32 Cells; Lane 2: Control siRNA; Lane 3: 50 pmoles PS1siRNA; Lane 4: 75 pmoles PS1 siRNA; Lane 5:100
pmoles PS1 siRNA. Values are mean ± SD (N = 5). *** p < 0.001 significantly different from csiRNA.
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Page 5 of 9Figure 4 Immunofluorescence analysis of Ab42 in methanol acetone fixed IMR-32 cells after transfected with PS1 siRNA and control
siRNA. Plane 1: Non siRNA transfected IMR-32 Cells; Plane 2: Control siRNA; Plane 3: 50 pmoles PS1 siRNA; Plane 4: 75 pmoles PS1 siRNA; Plane
5: 100 pmols PS1 siRNA. PS1 siRNA and control siRNA transfected IMR-32 cells were probed with Ab42 antibody. PS1 siRNA and control siRNA
transfected IMR-32 cells were probed with anti Ab42 antibody. The signal was revealed using FITC-conjugated secondary antibody and visualized
on a fluorescence microscope (o.m. 10X).
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Page 6 of 9Figure 5 Immunofluorescence analysis of PS1 expression in methanol acetone fixed IMR-32 cells after transfection with PS1 siRNA
and control siRNA. Plane 1: Non siRNA ransfected IMR-32 Cells; Plane 2: Control siRNA; Plane 3: 50 pmoles PS1siRNA; Plane 4: 75 pmoles PS1
siRNA; Plane 5: 100 pmoles PS1 siRNA. PS1 siRNA and control siRNA transfected IMR-32 cells were probed with PS1 antibody. PS1 siRNA and
control siRNA transfected IMR-32 cells were probed with anti PS1 antibody. The signal was revealed using FITC-conjugated secondary antibody
and visualized on a fluorescence microscope (o.m. 10X).
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inhibition of g-secretase with a variety of inhibitors [27],
which may play an important protective function in the
brain. Thus, the reinforcement of g-secretase activity
may be one of the reasons that cause AD. Alternatively,
the increase in Ab42 may be a marker of the reinforce-
ment of g-secretase activity, which may result in the
reinforcement of function of a number of g-secretase
substrates including Notch.
Conclusion
S oi nt h ep r e s e n ts t u d yw eh a v es h o w nt h a ts i R N A
against PS1 down regulates amyloid beta 42 production
in IMR32 cells. Taken together the results of the present
study suggest that in pathogenic condition we may target
PS1 for anti-amyloidogenic therapy in Alzheimer’sd i s -
ease as IMR32 is an AD featured cell line. These results
also reconfirm a role of PS1 in g-secretase activity.
Abbreviations
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